PulseExploreJournal ClubDebatesTrendingResearchersJournals
Instagram
HomeExploreJournal ClubTrending
Synapse
⌘+K
Synapse
February 29, 2012New England Journal of Medicine814 citationsOpen Access

Placebo-Controlled Trial of Amantadine for Severe Traumatic Brain Injury

View Full Paper
JGJoseph T. GiacinoJWJohn WhyteEBEmilia Bagiella

Key Points

  • To evaluate whether amantadine promotes and accelerates functional recovery in patients with prolonged disorders of consciousness following severe traumatic brain injury.
  • Randomized, placebo-controlled trial enrolling 184 patients in a vegetative or minimally conscious state 4 to 16 weeks after traumatic brain injury undergoing inpatient rehabilitation (NCT00970944).
  • Participants were randomly assigned to receive amantadine or placebo for 4 weeks, followed by a 2-week treatment-free washout period.
  • The primary outcome was the rate of functional recovery on the Disability Rating Scale (DRS; score range 0 to 29) analyzed using mixed-effects regression models.
  • During the 4-week treatment phase, functional recovery on the DRS was significantly faster with amantadine than placebo (difference in slope, 0.24 points per week; P=0.007).
  • The rate of improvement slowed in the amantadine group after discontinuation during weeks 5 and 6 compared with placebo (difference in slope, 0.30 points per week; P=0.02), resulting in similar overall DRS improvement from baseline to week 6.
  • Serious adverse event rates were not significantly different between the amantadine and placebo groups.

Abstract

BACKGROUND: Amantadine hydrochloride is one of the most commonly prescribed medications for patients with prolonged disorders of consciousness after traumatic brain injury. Preliminary studies have suggested that amantadine may promote functional recovery. METHODS: We enrolled 184 patients who were in a vegetative or minimally conscious state 4 to 16 weeks after traumatic brain injury and who were receiving inpatient rehabilitation. Patients were randomly assigned to receive amantadine or placebo for 4 weeks and were followed for 2 weeks after the treatment was discontinued. The rate of functional recovery on the Disability Rating Scale (DRS; range, 0 to 29, with higher scores indicating greater disability) was compared over the 4 weeks of treatment (primary outcome) and during the 2-week washout period with the use of mixed-effects regression models. RESULTS: During the 4-week treatment period, recovery was significantly faster in the amantadine group than in the placebo group, as measured by the DRS score (difference in slope, 0.24 points per week; P=0.007), indicating a benefit with respect to the primary outcome measure. In a prespecified subgroup analysis, the treatment effect was similar for patients in a vegetative state and those in a minimally conscious state. The rate of improvement in the amantadine group slowed during the 2 weeks after treatment (weeks 5 and 6) and was significantly slower than the rate in the placebo group (difference in slope, 0.30 points per week; P=0.02). The overall improvement in DRS scores between baseline and week 6 (2 weeks after treatment was discontinued) was similar in the two groups. There were no significant differences in the incidence of serious adverse events. CONCLUSIONS: Amantadine accelerated the pace of functional recovery during active treatment in patients with post-traumatic disorders of consciousness. (Funded by the National Institute on Disability and Rehabilitation Research; ClinicalTrials.gov number, NCT00970944.).

Ask AI
Helpful
Bookmark
Share
View Full Paper

Cite This Study

Giacino et al. (2012) studied this question.

synapsesocial.com/papers/69fc2e4081d49a44f4fa3c30https://doi.org/10.1056/nejmoa1102609
Ask AI
Helpful
Bookmark
Share
View Full Paper